Incretin therapy and islet pathology: a time for caution.
作者信息
Kahn Steven E
机构信息
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington, USA.
出版信息
Diabetes. 2013 Jul;62(7):2178-80. doi: 10.2337/db13-0520. Epub 2013 Apr 17.
Abstract
摘要
相似文献
1
Incretin therapy and islet pathology: a time for caution.肠促胰岛素治疗与胰岛病理学：需谨慎对待的时候了。
Diabetes. 2013 Jul;62(7):2178-80. doi: 10.2337/db13-0520. Epub 2013 Apr 17.
2
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.评论：巴特勒等人。在患有外分泌胰腺发育异常增加且有产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素疗法使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e18. doi: 10.2337/db13-0525.
3
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.评论：巴特勒等人。在患有外分泌胰腺发育异常增加及存在产生胰高血糖素的神经内分泌肿瘤可能性的人类中，肠促胰岛素疗法可使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e16-7. doi: 10.2337/db13-0690.
4
Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.对关于以下内容的评论的回应：巴特勒等人。在患有外分泌胰腺发育异常增加和产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素治疗使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e19-22. doi: 10.2337/db13-0996.
5
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.肠促胰岛素疗法对胰腺影响研究的重新分析：方法学缺陷
Diabetes Obes Metab. 2014 Jul;16(7):661-6. doi: 10.1111/dom.12257. Epub 2014 Jan 29.
6
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.肠促胰岛素疗法不会增加年轻雄性小鼠的β细胞量或改变胰腺组织学。
Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.
7
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.外分泌和内分泌胰腺在具有外分泌胰腺发育不良增加的人类中随着肠促胰岛素治疗而显著扩张，并且具有产生胰高血糖素的神经内分泌肿瘤的潜力。
Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.
8
Novo Nordisk incretin leadership summit, Cape Town.
Cardiovasc J Afr. 2012 Jun;23(5):288-92.
9
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.靶向2型糖尿病中的β细胞量：基于肠促胰岛素的新药的前景与局限
Endocr Rev. 2008 May;29(3):367-79. doi: 10.1210/er.2007-0031. Epub 2008 Feb 21.
10
Lipotoxicity impairs incretin signalling.脂毒性损害肠促胰岛素信号转导。
Diabetologia. 2013 Feb;56(2):231-3. doi: 10.1007/s00125-012-2788-6. Epub 2012 Nov 28.
引用本文的文献
1
Incretin based therapy and pancreatic cancer: Realising the reality.基于肠降血糖素的治疗与胰腺癌：认清现实。
World J Gastroenterol. 2022 Jul 7;28(25):2881-2889. doi: 10.3748/wjg.v28.i25.2881.
2
Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine.使用新制备的单克隆抗体对抗糖尿病药物阿格列汀进行免疫组织化学研究：其在大鼠小肠中的精确定位
Acta Histochem Cytochem. 2019 Feb 28;52(1):27-34. doi: 10.1267/ahc.18036. Epub 2019 Feb 23.
3
Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis.二肽基肽酶-4抑制剂药物与急性胰腺炎风险之间的关联：一项荟萃分析。
Medicine (Baltimore). 2017 Dec;96(48):e8952. doi: 10.1097/MD.0000000000008952.
4
Effects of Linagliptin on Pancreatic Cells of Type 1 Diabetic Mice.利格列汀对1型糖尿病小鼠胰岛β细胞的影响。
J Endocr Soc. 2017 Aug 31;1(10):1224-1234. doi: 10.1210/js.2017-00253. eCollection 2017 Oct 1.
5
Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine Pancreas.糖尿病与正常生理状态下的胰腺体积和脂肪沉积：内分泌胰腺与外分泌胰腺相互作用的考量
Rev Diabet Stud. 2016 Summer-Fall;13(2-3):132-147. doi: 10.1900/RDS.2016.13.132. Epub 2016 Aug 10.
6
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass.基于肠促胰岛素的治疗对β细胞功能和质量影响的最新进展
Diabetes Metab J. 2016 Apr;40(2):99-114. doi: 10.4093/dmj.2016.40.2.99.
7
Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.在日本超重/肥胖2型糖尿病患者中，与二甲双胍相比，利拉鲁肽单药治疗对β细胞功能和胰腺酶的影响：KIND-LM随机试验的亚组分析
Clin Drug Investig. 2015 Oct;35(10):675-84. doi: 10.1007/s40261-015-0331-5.
8
Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.胰高血糖素样肽-1受体在正常及患病人类甲状腺和胰腺中的表达
Mod Pathol. 2015 Mar;28(3):391-402. doi: 10.1038/modpathol.2014.113. Epub 2014 Sep 12.
9
Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.二肽基肽酶-4抑制剂与胰腺癌：一项队列研究。
Diabetes Obes Metab. 2014 Dec;16(12):1247-56. doi: 10.1111/dom.12379. Epub 2014 Sep 10.
10
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.二肽基肽酶 4 抑制剂的安全性：观点综述。
Ther Adv Drug Saf. 2014 Jun;5(3):138-46. doi: 10.1177/2042098614523031.
本文引用的文献
1
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).糖尿病血糖降低方法的原理和设计：一项比较效果研究（GRADE）。
Diabetes Care. 2013 Aug;36(8):2254-61. doi: 10.2337/dc13-0356. Epub 2013 May 20.
2
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.外分泌和内分泌胰腺在具有外分泌胰腺发育不良增加的人类中随着肠促胰岛素治疗而显著扩张，并且具有产生胰高血糖素的神经内分泌肿瘤的潜力。
Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.
3
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.基于胰高血糖素样肽 1 的治疗与 2 型糖尿病患者急性胰腺炎住院风险的相关性：一项基于人群的匹配病例对照研究。
JAMA Intern Med. 2013 Apr 8;173(7):534-9. doi: 10.1001/jamainternmed.2013.2720.
4
Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes.患有1型糖尿病相关自身抗体且有患病风险个体的胰腺器官重量。
JAMA. 2012 Dec 12;308(22):2337-9. doi: 10.1001/jama.2012.15008.
5
Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes.成年 1 型糖尿病患者的胰腺体积减小。
J Clin Endocrinol Metab. 2012 Nov;97(11):E2109-13. doi: 10.1210/jc.2012-1815. Epub 2012 Aug 9.
6
The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.人 GLP-1 类似物利拉鲁肽与胰腺：三种动物模型中胰腺结构无改变的证据。
Diabetes. 2012 May;61(5):1243-9. doi: 10.2337/db11-0936. Epub 2012 Feb 14.
7
Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.二肽基肽酶-4 抑制剂可减少链脲佐菌素诱导的小鼠糖尿病模型中胰岛β细胞的死亡和胰岛α细胞的增殖。
Diabetologia. 2012 Feb;55(2):404-12. doi: 10.1007/s00125-011-2365-4. Epub 2011 Nov 10.
8
Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans.胃旁路手术增强了人类胰高血糖素样肽 1 刺激的餐后胰岛素分泌。
Diabetes. 2011 Sep;60(9):2308-14. doi: 10.2337/db11-0203.
9
Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.胰高血糖素受体缺陷小鼠中的胰腺神经内分泌肿瘤。
PLoS One. 2011;6(8):e23397. doi: 10.1371/journal.pone.0023397. Epub 2011 Aug 10.
10
β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition.在人类 2 型糖尿病中，β 细胞的丧失和β 细胞凋亡与胰岛淀粉样沉积有关。
Am J Pathol. 2011 Jun;178(6):2632-40. doi: 10.1016/j.ajpath.2011.02.036.
Zotero 插件